ArticleInternational journal of cancer2018
Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review.BMC cancer · 2022Pooled it
- Etoposide activates CD8Journal for immunotherapy of cancer · 2025Article
- Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.Cancer epidemiology · 2024Article
- Children's Oncology Group's 2023 blueprint for research: Epidemiology.Pediatric blood & cancer · 2023Article
- MFNG is an independent prognostic marker for osteosarcoma.European journal of medical research · 2023Article
- Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group.Journal of the National Cancer Institute · 2023Article
- Recent Advances in Pediatric Cancer Research.Cancer research · 2021Review
- The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- The Emerging Physiological Role of AGMO 10 Years after Its Gene Identification.Life (Basel, Switzerland) · 2021Review
- Immune-Related LncRNAs Affect the Prognosis of Osteosarcoma, Which Are Related to the Tumor Immune Microenvironment.Frontiers in cell and developmental biology · 2021Article
- A Fast and Accurate Method for Genome-Wide Time-to-Event Data Analysis and Its Application to UK Biobank.American journal of human genetics · 2020Article
- The Effects of Interleukin-33 (IL-33) on Osteosarcoma Cell Viability, Apoptosis, and Epithelial-Mesenchymal Transition are Mediated Through the PI3K/AKT Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Functional variant of IL33 is associated with survival of osteosarcoma patients.Journal of bone oncology · 2020Article
- Risk-modeling of dog osteosarcoma genome scans shows individuals with Mendelian-level polygenic risk are common.BMC genomics · 2019Article
- Relationship of common variants in Interleukin 33 gene with susceptibility and prognosis of osteosarcoma in Han Chinese population.Journal of Cancer · 2019Article
- Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Article
- The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine.Frontiers in immunology · 2018Review
- IL-33 in Tumor Immunity: Nothing to Sneeze At.Critical reviews in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 13 institutions in 7 countries.
Funding
Abstract
Survival rates for osteosarcoma, the most common primary bone cancer, have changed little over the past three decades and are particularly low for patients with metastatic disease. We conducted a multi-institutional genome-wide association study (GWAS) to identify germline genetic variants associated with overall survival in 632 patients with osteosarcoma, including 523 patients of European ancestry and 109 from Brazil. We conducted a time-to-event analysis and estimated hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazards models, with and without adjustment for metastatic disease. The results were combined across the European and Brazilian case sets using a random-effects meta-analysis. The strongest association after meta-analysis was for rs3765555 at 9p24.1, which was inversely associated with overall survival (HR = 1.76; 95% CI 1.41-2.18, p = 4.84 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.